glp-1 drugs and addiction medications get at the heart of addiction: study – WashU Medicine What to know about how
Description
Niazi S, Gnesin F, Thein AS, et al
Nevertheless, GLP-1RAs are a promising therapeutic option for DKD
Lancet 2023, 402, 613626
doi: 10.1210/jcem-63-2-492
Rise of Dual and Triple Agonists: Beyond GLP-1, newer drugs target GIP and glucagon receptors for enhanced efficacy (e.g., Tirzepatide, Retatrutide)
Compensation for participation is available
